|
Mar 3
|
Ligand to Participate in March Investor Conferences
|
|
Mar 3
|
LGND: First Steps into Cell & Gene Therapy
|
|
Feb 28
|
Ligand Pharmaceuticals Inc (LGND) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...
|
|
Feb 27
|
Ligand: Q4 Earnings Snapshot
|
|
Feb 27
|
Ligand Reports Fourth Quarter and Full Year 2024 Financial Results
|
|
Feb 25
|
Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences
|
|
Sep 6
|
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
|
|
Aug 27
|
Insider Sale: President & COO Matthew Korenberg Sells 18,858 Shares of Ligand ...
|
|
Jul 30
|
Hidden Gems Undiscovered Companies with Strong Fundamentals For July 2024
|
|
Jul 30
|
Undiscovered Gems In The United States For July 2024
|
|
Jul 23
|
Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024
|
|
Jul 9
|
Ligand Pharmaceuticals to acquire APEIRON Biologics for $100m
|
|
Jul 8
|
Ligand to Acquire Apeiron for $100 Million in Cash, Plus Up to $28 Million Based on Royalties
|
|
Jul 8
|
Ligand to buy Apeiron; Roche reports another TIGIT setback
|
|
Jul 8
|
Ligand to Acquire APEIRON Biologics AG for $100 Million
|
|
Jun 24
|
Bristol Myers' (BMY) Krazati Gets FDA Nod for Colorectal Cancer
|
|
Jun 19
|
Roche (RHHBY), Ascidian Team Up for RNA Exon Editing Therapeutics
|
|
Jun 19
|
Terns (TERN) Gains 13.6% YTD: Will the Momentum Continue?
|
|
Jun 19
|
The past three years for Ligand Pharmaceuticals (NASDAQ:LGND) investors has not been profitable
|
|
Jun 18
|
Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults
|